Urogenit Tract Infect.  2015 Oct;10(2):67-73. 10.14777/uti.2015.10.2.67.

Uropathogens Based on Antibiotic Susceptibility

• Lee SW
• Kim YH

• KMID: 2319430
• DOI: http://doi.org/10.14777/uti.2015.10.2.67

Abstract

Urinary tract infections are one of the most commonly encountered infections in clinical practice. Due to the emergence of and increase in urinary tract bacteria that are resistant to trimethoprim-sulfamethoxazole, penicillin, cephalosporins, and fluoroquinolones, selection of appropriate antibiotics in treatment of these infections is important. In addition, the emergence of extended-spectrum beta-lactamase-producing organisms makes antibiotic selection difficult. This article provides a review of disease-specific uropathogens and their susceptibilities to antimicrobial agents.

Keyword

Anti-infective agents

MeSH Terms

Anti-Bacterial Agents
Anti-Infective Agents
Bacteria
Cephalosporins
Fluoroquinolones
Penicillins
Trimethoprim, Sulfamethoxazole Drug Combination
Urinary Tract
Urinary Tract Infections
Anti-Bacterial Agents
Anti-Infective Agents
Cephalosporins
Fluoroquinolones
Penicillins

Reference

1.Ronald AR., Nicolle LE., Stamm E., Krieger J., Warren J., Schaeffer A, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents. 2001. 17:343–8.

2.Valiquette L. Urinary tract infections in women. Can J Urol. 2001. 8(Suppl 1):6–12.

3.Hooton TM., Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997. 11:551–81.

4.Kim ME., Ha US., Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents. 2008. 31(Suppl 1):S15–8.

5.Prabhu A., Taylor P., Konecny P., Brown MA. Pyelonephritis: what are the present day causative organisms and antibiotic susceptibilities? Nephrology (Carlton). 2013. 18:463–7.

6.Hwang BY., Lee JG., Park DW., Lee YJ., Kim SB., Eom JS, et al. Antimicrobial susceptibility of causative microorganisms in adults with acute pyelonephritis at one university-affiliated hospital in southwestern Seoul. Infect Chemother. 2003. 35:277–82.

7.Lee H., Park HC., Yoon HB., Han SS., Cha RH., Oh KH, et al. Causative organisms and antibiotics sensitivity in community acquired acute pyelonephritis. Korean J Nephrol. 2008. 27:688–95.

8.Ha US., Kim ME., Kim CS., Shim BS., Han CH., Lee SD, et al. Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents. 2008. 31(Suppl 1):S96–101.

9.Jemal A., Bray F., Center MM., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin. 2011. 61:69–90.

10.Loeb S., Carter HB., Berndt SI., Ricker W., Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011. 186:1830–4.

11.Djavan B., Waldert M., Zlotta A., Dobronski P., Seitz C., Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001. 166:856–60.

12.Aus G., Ahlgren G., Bergdahl S., Hugosson J. Infection after transrectal core biopsies of the prostate: risk factors and antibiotic prophylaxis. Br J Urol. 1996. 77:851–5.

13.Rietbergen JB., Kruger AE., Kranse R., Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997. 49:875–80.

14.Yu X., Susa M., Weile J., Knabbe C., Schmid RD., Bachmann TT. Rapid and sensitive detection of fluoroquinolone-resistant Escherichia coli from urine samples using a genotyping DNA microarray. Int J Med Microbiol. 2007. 297:417–29.

15.Tal R., Livne PM., Lask DM., Baniel J. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol. 2003. 169:1762–5.

16.Otrock ZK., Oghlakian GO., Salamoun MM., Haddad M., Bizri AR. Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol. 2004. 25:873–7.

17.Nam RK., Saskin R., Lee Y., Liu Y., Law C., Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010. 183:963–8.

18.Ozden E., Bostanci Y., Yakupoglu KY., Akdeniz E., Yilmaz AF., Tulek N, et al. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology. 2009. 74:119–23.

19.Liss MA., Johnson JR., Porter SB., Johnston B., Clabots C., Gillis K, et al. Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis. 2015. 60:979–87.

20.Bang JH., Choe HS., Lee DS., Lee SJ., Cho YH. Microbiological characteristics of acute prostatitis after transrectal prostate biopsy. Korean J Urol. 2013. 54:117–22.

21.Lee DS., Lee CB., Lee SJ. Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol. 2010. 51:492–7.

22.Oteo J., Delgado-Iribarren A., Vega D., Bautista V., Rodríguez MC., Velasco M, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents. 2008. 32:534–7.

23.Rodríguez-Baño J., Picón E., Gijón P., Hernández JR., Ruíz M., Peña C, et al. Spanish Network for Research in Infectious Diseases (REIPI). Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010. 50:40–8.

24.Rooney PJ., O'Leary MC., Loughrey AC., McCalmont M., Smyth B., Donaghy P, et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother. 2009. 64:635–41.

25.Kelesidis T., Karageorgopoulos DE., Kelesidis I., Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008. 62:895–904.

26.Lu CT., Chuang YC., Sun W., Liu YC., Cheng YJ., Lu PL, et al. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2008. 32(Suppl 3):S179–83.